Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telotristat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 known ✓ | P17752 | 20/20 | 1.00 |
| ▸ | TPH2 known ✓ | Q8IWU9 | 5/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | CCKAR | P32238 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 0.86 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.86 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.86 |
| ▸ | MC3R | P41968 | 1/20 | 0.86 |
| ▸ | HTR3A | P46098 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telotristat SCHEMBL611625 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| Telotristat SCHEMBL611624 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| Telotristat SCHEMBL612369 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| Telotristat SCHEMBL611626 | 1.00 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| Telotristat SCHEMBL3654183 | 0.97 | TPH1 (0.94) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL12527320 | 0.95 | TPH1 (0.90) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL610573 | 0.94 | TPH1 (0.89) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL610574 | 0.94 | TPH1 (0.89) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL612946 | 0.94 | TPH1 (0.89) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL19672627 | 0.94 | TPH1 (0.89) | TPH1TPH2ADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260014149-A1 | METHODS OF TREATING MERKEL CELL CARCINOMA WITH TRYPTOPHAN HYDOXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | claimed |
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| US-20250108137-A1 | APTAMERS SPECIFIC TO EBV-ASSOCIATED MALIGNANCIES AND THEIR APPLICATIONS IN CANCER IMAGING AND THERAPIES | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-04-03 | — | — | US | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250025583-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-01-23 | — | — | US | claimed |
| WO-2025019334-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2025-01-23 | — | — | WO | claimed |
| EP-4476345-A1 | APTAMERS SPECIFIC TO EBV-ASSOCIATED MALIGNANCIES AND THEIR APPLICATIONS IN CANCER IMAGING AND THERAPIES | The Chinese University Of Hong Kong (HK) | 2024-12-18 | — | — | EP | claimed |
| EP-2635569-A1 | CRYSTALLINE FORMS OF ( S ) - 2 - AMINO - 3 - (4 - ( 2 - AMINO - 6 - ( (R) - 1 - (4 - CH LORO-2- (3 -METHYL- 1H- PYRAZOL- 1 -YL) PHENYL) - 2, 2, 2 - TRIFLUOROETHOXY) PYRIMIDIN- 4 - YL) PHENYL) PROPANOIC ACID | Lexicon Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | claimed |
| US-20130172376-A1 | SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE | LEXICON PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | claimed |
| EP-2589600-A1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-05-08 | — | — | EP | claimed |
| WO-2013059146-A1 | SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | claimed |
| US-20120122904-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID | TERSERA THERAPEUTICS LLC | 2012-05-17 | — | — | US | claimed |
| WO-2012061576-A1 | CRYSTALLINE FORMS OF ( S ) - 2 - AMINO - 3 - (4 - ( 2 - AMINO - 6 - ( (R) - 1 - (4 - CH LORO-2- (3 -METHYL- 1H- PYRAZOL- 1 -YL) PHENYL) - 2, 2, 2 - TRIFLUOROETHOXY) PYRIMIDIN- 4 - YL) PHENYL) PROPANOIC ACID | LEXICON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | claimed |
| US-7709493-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | claimed |
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TERSERA THERAPEUTICS LLC | 2009-11-19 | — | — | US | claimed |
| EP-2091940-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-26 | — | — | EP | claimed |
| WO-2008073933-A2 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | KRAS, NRAS, HRAS | TPH1 2987/4885TPH2 3679/4885ADORA3 2568/4885 |
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TPH1, TPH2, PAH | TPH1 1/4885TPH2 2/4885ADORA3 364/4885 |
| US-20120122904-A1 | SOLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID | SLC7A1, SLC6A1, SLC6A11 | TPH1 898/4885TPH2 1026/4885ADORA3 214/4885 |
| US-20130172376-A1 | SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE | TPP1, TPP2, TMPO | TPH1 696/4885TPH2 709/4885ADORA3 3175/4885 |
| US-20250025583-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | IL15RA, IL15, SSTR5 | TPH1 990/4885TPH2 1799/4885ADORA3 970/4885 |
| US-20260014149-A1 | METHODS OF TREATING MERKEL CELL CARCINOMA WITH TRYPTOPHAN HYDOXYLASE INHIBITORS | TPH1, TPH2, CD274 | TPH1 1/4885TPH2 2/4885ADORA3 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.